Efficacy and safety of mecasermin rinfabate

Expert Opinion on Biological Therapy

Volumn 6, Issue 5, 2006, Pages 533-538

  Kemp, Stephen F ^a   Fowlkes, John L ^b   Thrailkill, Kathryn M ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

GHIS; Growth hormone; Growth hormone insensitivity syndrome; Hypoglycaemia; Insulin like growth factors; Laron syndrome; Short stature

Indexed keywords

MECASERMIN RINFABATE;

CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GROWTH DISORDER; HUMAN; HYPOGLYCEMIA; REVIEW;

BURNS; CLINICAL TRIALS; DIABETES MELLITUS; DRUG COMBINATIONS; GROWTH DISORDERS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS;

EID: 33646555490     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.5.533     Document Type: Review

References (41)

1. SALMON WD JR, DAUGHADAY WH: A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J. Lab. Clin. Med. (1957) 49:825-836.
2. DAUGHADAY WH, HALL K, RABEN MS, SALMON WD JR, VAN DEN BRANDE JL, VAN WYK JJ: Somatomedin: proposed designation for sulphation factor. Nature (1972) 235:107.
3. RINDERKNECHT E, HUMBEL RE: Primary structure of human insulin-like growth factor II. FEBS Lett. (1978) 89:283-286.
4. RINDERKNECHT E, HUMBEL RE: The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J. Biol. Chem. (1978) 253:2769-2776.
5. RANKE MB: Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol. Metab. (2005) 16:190-197.
6. JANSEN M, VAN SCHAIK FM, RICKER AT et al.: Sequence of cDNA encoding human insulin-like growth factor I precursor. Nature (1983) 306:609-611.
7. SHAW NJ, FRASER NC, ROSE S, CRABTREE NJ, BOIVIN CM: Bone density and body composition in children with growth hormone insensitivity syndrome receiving recombinant IGF-I. Clin. Endocrinol. (Oxford) (2003) 59:487-491.
8. THRAILKILL KM: Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility. Diabetes Technol. Ther. (2000) 2:69-80.
9. CARRO E, TREJO JL, NUNEZ A, TORRES-ALEMAN I: Brain repair and neuroprotection by serum insulin-like growth factor I. Mol. Neurobiol. (2003) 27:153-162.
10. VINCENT AM, MOBLEY BC, HILLERA, FELDMAN EL: IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiol. Dis. (2004) 16:407-416.
11. FESTOFF BW: Amyotrophic lateral sclerosis: current and future treatment strategies. Drugs (1996) 51:28-44.
12. BURROUGHS KD, DUNN SE, BARRETT JC, TAYLOR JA: Insulin-like growth factor-I: a key regulator of human cancer risk? J. Natl. Cancer Inst. (1999) 91:579-581.
13. JONES JI, CLEMMONS DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. (1995) 16:3-34.
14. BAXTER RC, MARTIN JL: Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling. Proc. Natl. Acad. Sci. USA (1989) 86:6898-6902.
15. RECHLER MM: Insulin-like growth factor binding proteins. Vitam. Horm. (1993) 47:1-114.
16. RANKE MB, ELMLINGER M: Functional role of insulin-like growth factor binding proteins. Horm. Res. (1997) 48(Suppl. 4):9-15.
17. CAMACHO-HUBNER C, WOODS KA, MIRAKI-MOUD F et al.: Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion. J. Clin. Endocrinol. Metab. (1999) 84:1611-1616. • A case report and description of the use of IGF-I as a treatment for a patient with an IGF-I gene deletion.
18. GRAHNEN A, KASTRUP K, HEINRICH U et al.: Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. Acta Paediatr. Suppl. (1993) 82(Suppl. 391):9-13; discussion 14. • This supplement is a good source of pharmacokinetic data on the administration of unbound IGF-I in healthy individuals and GHIS patients.
19. RANKE MB: Treatment of growth hormone insensitivity syndrome (GHIS) with insulin-like growth factor (IGF-I). Baillieres Clin. Endocrinol. Metab. (1996) 10:401-410.
20. LARON Z, LILOS P, KLINGER B: Growth curves for Laron syndrome. Arch. Dis. Child. (1993) 68:768-770.
21. ROSENBLOOM A: IGF-I treatment of growth hormone insensitivity. In: IGF in Health and Disease. Rosenfeld RG, Roberts CT (Eds), Humana Press, Totowa, NJ, USA (2000):739-770. • An excellent summary of a study investigating the treatment of a large cohort of GHIS patients with unbound IGF-I.
22. SAVAGE MO, CAMACHO-HUBNER C, DUNGER DB: Therapeutic applications of the insulin-like growth factors. Growth Horm. IGF Res. (2004) 14:301-308. • A thorough theoretical discussion of the possible therapeutic uses for IGF-I and IGF-I/IGFBP-3.
23. AZCONA C, PREECE MA, ROSE SJ et al.: Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype. Clin. Endocrinol. (Oxford) (1999) 51:787-792.
24. RANKE MB, SAVAGE MO, CHATELAIN PG, PREECE MA, ROSENFELD RG, WILTON P: Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm. Res. (1999) 51:128-134.
25. BACKELJAUW PF, UNDERWOOD LE: Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J. Clin. Endocrinol. Metab. (2001) 86:1504-1510.
26. WOODS KA, CAMACHO-HUBNER C, SAVAGE MO, CLARK AJ: Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N. Engl. J. Med. (1996) 335:1363-1367.
27. WOODS KA, CAMACHO-HUBNER C, BERGMAN RN, BARTER D, CLARK AJ, SAVAGE MO: Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J. Clin. Endocrinol. Metab. (2000) 85:1407-1411.
28. HERNDON DN, RAMZY PI, DEBROY MA et al.: Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment. Ann. Surg. (1999) 229:713-720; discussion 720-712.
29. JESCHKE MG, BARROW RE, HERNDON DN: Insulinlike growth factor I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children. Ann. Surg. (2000) 231:246-252.
30. JESCHKE MG, HERNDON DN, VITA R, TRABER DL, JAUCH KW, BARROW RE: IGF-I/BP-3 administration preserves hepatic homeostasis after thermal injury which is associated with increases in no and hepatic NF-kappa B. Shock (2001) 16:373-379.
31. SPIES M, WOLF SE, BARROW RE, JESCHKE MG, HERNDON DN: Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children. Crit. Care Med. (2002) 30:83-88.
32. DEBROY MA, WOLF SE, ZHANG XJ et al.: Anabolic effects of insulin-like growth factor in combination with insulin-like growth factor binding protein-3 in severely burned adults. J. Trauma (1999) 47:904-910; discussion 910-901.
33. CAMACHO-HUBNER C, STORR HL, MIRAKI-MOUD F et al.: Pharmacokinetic studies of rhIGF-I/rhIGFBP-3 complex administered to patients with growth hormone insensitivity syndrome (GHIS). Paper presented at the Endocrine Society's 85th Annual Meeting. Philadelphia, PA, USA (12-22 June 2003). • Although only an abstract, this is a good report of the pharmacokinetics of the IGF-I/IGFBP-3 complex.
34. BOONEN S, ROSEN C, BOUILLON R et al.: Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteopororic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J. Clin. Endocrinol. Metab. (2002) 87:1593-1599.
35. CLEMMONS DR, MOSES AC, MCKAY MJ, SOMMER A, ROSEN DM, RUCKLE J: The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J. Clin. Endocrinol. Metab. (2000) 85:1518-1524.
36. CLEMMONS DR, MOSES AC, SOMMER A et al.: Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm. IGF Res. (2005) 15:265-274.
37. MOSES AC: Insulin resistance and type 2 diabetes mellitus: is there a therapeutic role for IGF-1? Endocr. Dev. (2005) 9:121-134.
38. GRINSPOON S, THOMAS L, MILLER K, HERZOG D, KLIBANSKI A: Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J. Clin. Endocrinol. Metab. (2002) 87:2883-2891.
39. QUATTRIN T, THRAILKILL K, BAKER L et al.: Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile. Diabetes Care (1997) 20:374-380.
40. GUEVARA-AGUIRRE J, VASCONEZ O, MARTINEZ V et al.: A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J. Clin. Endocrinol. Metab. (1995) 80:1393-1398. •• An excellent report on treatment of a large cohort of GHIS patients with unbound IGF-I.
41. NO AUTHORS LISTED: Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. (2005) 6:120-127.